Tilray Brands (NASDAQ:TLRY) Trading Down 2.7% – Here’s Why

Tilray Brands, Inc. (NASDAQ:TLRY) was down 2.7% on Wednesday . The company traded as low as $4.71 and last traded at $4.75. Approximately 3,387,659 shares were traded during mid-day trading, a decline of 22% from the average session volume of 4,329,433 shares. The stock had previously closed at $4.88.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray highlighted new consumer-facing growth initiatives, including the launch of Hi*Ball Energy in the U.K., where it will be sold online through Amazon and BrewDog’s website, broadening the company’s beverage distribution footprint. Tilray takes Hi*Ball energy brand to UK
• Positive Sentiment: Breckenridge Distillery, a Tilray subsidiary, released a limited single-barrel bourbon collection, adding another premium product update that supports Tilray’s diversification beyond cannabis. Breckenridge Distillery Releases Limited Single Barrel Bourbon Collection
• Positive Sentiment: BrewDog also launched a Father’s Day campaign in the U.K., another sign Tilray’s beverage brands are staying active in marketing and retail channels. BrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat Free
• Neutral Sentiment: Several market roundup pieces continue to list Tilray among cannabis stocks to watch, keeping the name visible but not adding a clear fundamental catalyst. Top Cannabis Stocks To Keep An Eye On – June 18th
• Neutral Sentiment: Analysts’ consensus rating remains “Hold,” suggesting Wall Street is not yet convinced the recent brand news will be enough to drive a sustained turnaround. Tilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: A Seeking Alpha commentary piece says Tilray may look cheap on the surface, but shareholders still need proof, reinforcing investor skepticism about earnings execution and profitability. Tilray Looks Cheap On The Surface, But Shareholders Still Need Proof

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TLRY shares. TD Cowen dropped their price objective on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. ATB Cormark Capital Markets decreased their target price on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research note on Thursday, April 2nd. Weiss Ratings lowered shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Roth Mkm raised shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Thursday, April 2nd. Finally, Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tilray Brands presently has an average rating of “Hold” and an average price target of $11.50.

Tilray Brands Stock Performance

The business has a 50 day simple moving average of $5.81 and a two-hundred day simple moving average of $7.36. The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19. The stock has a market cap of $551.28 million, a price-to-earnings ratio of -0.35 and a beta of 1.88.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The business had revenue of $206.73 million for the quarter, compared to analysts’ expectations of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same quarter in the prior year, the firm earned ($0.87) earnings per share. As a group, equities analysts anticipate that Tilray Brands, Inc. will post -0.58 EPS for the current year.

Insider Activity

In related news, Director David G. Hopkinson sold 33,556 shares of Tilray Brands stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total value of $232,878.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.84% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TLRY. Oppenheimer & Co. Inc. acquired a new stake in shares of Tilray Brands in the 3rd quarter valued at about $25,000. Clearstead Advisors LLC grew its stake in Tilray Brands by 437.3% in the third quarter. Clearstead Advisors LLC now owns 21,625 shares of the company’s stock worth $37,000 after purchasing an additional 17,600 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new position in Tilray Brands in the fourth quarter worth about $38,000. Cerity Partners LLC increased its holdings in Tilray Brands by 98.5% in the second quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after buying an additional 45,929 shares during the last quarter. Finally, Marex Group plc bought a new stake in Tilray Brands in the second quarter valued at about $40,000. 9.35% of the stock is owned by institutional investors and hedge funds.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.